These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. Hashem AM; Flaman AS; Farnsworth A; Brown EG; Van Domselaar G; He R; Li X PLoS One; 2009 Dec; 4(12):e8350. PubMed ID: 20020057 [TBL] [Abstract][Full Text] [Related]
3. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765 [TBL] [Abstract][Full Text] [Related]
4. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Abed Y; Nehmé B; Baz M; Boivin G Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor. Zhang H; Wang K; Zhu H; Zhao X; Zhao H; Lei Z; Chen B; Yang F; Liu K; Zhang K; Wang J; Tian Y Eur J Med Chem; 2020 Aug; 200():112423. PubMed ID: 32512482 [TBL] [Abstract][Full Text] [Related]
6. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. Barrett S; Mohr PG; Schmidt PM; McKimm-Breschkin JL PLoS One; 2011; 6(8):e23627. PubMed ID: 21858186 [TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542 [TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870 [TBL] [Abstract][Full Text] [Related]
9. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Abed Y; Baz M; Boivin G Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366 [TBL] [Abstract][Full Text] [Related]
10. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. Ikematsu H; Kawai N; Kashiwagi S J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919 [TBL] [Abstract][Full Text] [Related]
11. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses. Ilyushina NA; Govorkova EA; Gray TE; Bovin NV; Webster RG PLoS Pathog; 2008 Apr; 4(4):e1000043. PubMed ID: 18404209 [TBL] [Abstract][Full Text] [Related]
12. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses. Singh A; Soliman ME Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922 [TBL] [Abstract][Full Text] [Related]
14. Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir. Tai SH; Agafitei O; Gao Z; Liggins R; Petric M; Withers SG; Niikura M Virus Res; 2015 Dec; 210():126-32. PubMed ID: 26247418 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of NH Wang K; Yang F; Wang L; Liu K; Sun L; Lin B; Hu Y; Wang B; Cheng M; Tian Y Eur J Med Chem; 2017 Dec; 141():648-656. PubMed ID: 29107426 [TBL] [Abstract][Full Text] [Related]
17. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. Duwe S; Schweiger B J Virol Methods; 2008 Nov; 153(2):134-41. PubMed ID: 18725246 [TBL] [Abstract][Full Text] [Related]
18. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1. Yongkiettrakul S; Nivitchanyong T; Pannengpetch S; Wanitchang A; Jongkaewwattana A; Srimanote P Virus Res; 2013 Aug; 175(2):128-33. PubMed ID: 23639424 [TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection. Charyasriwong S; Watanabe K; Rahmasari R; Matsunaga A; Haruyama T; Kobayashi N Arch Med Res; 2015 Jan; 46(1):8-16. PubMed ID: 25523147 [TBL] [Abstract][Full Text] [Related]
20. Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase. Xie Y; Xu D; Huang B; Ma X; Qi W; Shi F; Liu X; Zhang Y; Xu W J Med Chem; 2014 Oct; 57(20):8445-58. PubMed ID: 25255388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]